Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | CELL | Common Stock | Sale | -$30.8K | -6.2K | -3.26% | $4.97* | 184K | May 13, 2022 | Direct | F1, F2 |
Id | Content |
---|---|
F1 | The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. |
F2 | On May 13, 2022, the reporting person filed a Form 4 reporting the sale of 7,531 shares of common stock at $4.97 per share pursuant to a Rule 10b5-1 trading plan. The total amount reported sold on May 13, 2022 was based on incorrect information provided by the reporting person's broker. The total number of shares sold on May 13, 2022 was 6,198, rather than 7,531. |
President - Antibody Therapeutics